Alzheimer Disease Clinical Trial
Official title:
Effects of Visual Arts Training on Dementia
| Verified date | July 2016 |
| Source | York University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Institutional Review Board |
| Study type | Interventional |
The study will use a randomized controlled trial to test the efficacy of two interventions
(visual arts and music) for individuals with dementia, focusing on dementia of the
Alzheimer's type (DAT). Interventions will be run for 10 weeks in dementia day centers
and/or retirement residences. Participants will be tested before and after the intervention
on a battery of cognitive, affective, and behavioural measures. They will be compared to a
waitlist control group who don't receive the intervention.
The purpose of our research is twofold: treatment of symptoms and improved quality of life
during disease progression in dementia. For the primary aim, the investigators are examining
the potential of arts interventions on declining functions in dementia (memory, mood, and
behavior) to investigate potential treatment effects. Secondly, quality of life will be
measured, with the aim of looking beyond disease progression to contribute to an overall
positive patient experience. Research has indicated the need for non-pharmacological
treatments to be used as a first line of action against dementia symptoms and development.
While, in best practice, pharmacological treatments should be used as a second-line
approach.
Note: Music intervention dropped prior to study initiation.
| Status | Completed |
| Enrollment | 23 |
| Est. completion date | December 2015 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 65 Years and older |
| Eligibility |
Inclusion Criteria: - dementia Exclusion Criteria: - known comorbid cognitive or neurological impairments |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| York University |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Montreal Cognitive Assessment (MOCA, change measure) | Designed by Nasreddine (2005) for overall cognitive assessment | baseline and 8 weeks | No |
| Primary | Working memory (change measure) | Visual (body part pointing test, Stopford et al, 2010), auditory (digit span test, Weschler, 2008) | baseline and 8 weeks | No |
| Primary | Rey-Osterreith test of long-term memory (change measure) | Rey-Osterreith Complex Figure Recognition, Rey-Osterreith Figure Copy, Rey-Osterreith verbal task (Osterreith, 1944; Schmidt, 1996) | baseline and 8 weeks | No |
| Primary | Trails test of set-shifting (change measure) | Measure of set-shifting/task switching | baseline and 8 weeks | No |
| Primary | Dual task for visual and auditory search (change measure) | designed by Baddeley (2001) | baseline and 8 weeks | No |
| Secondary | Behavioural psychiatric peformance (time-to-event measure) | Neuropsychiatric Inventory (NPI; Cummings, 2009) | from date of randomization upto 8 weeks | No |
| Secondary | Quality of Life (change measure) | Questionnaire on well-being (Kerner, Patterson, Grant, & Kaplan, 1998) to be filled out by caregivers | baseline and 8 weeks | No |
| Secondary | Visual analog mood scale | Measure of mood designed by Stern et al (2010) and Temple et al (2004) | baseline and 8 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
| Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
| Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
| Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
| Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
| Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
| Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
| Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
| Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
| Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
| Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
| Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
| Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
| Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
| Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
| Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
| Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
| Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
| Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |